Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022 Report

“Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the oncolytic virus therapy market. Currently there are 2 oncolytic virus therapies commercially available in the market. This report analyzes the ongoing clinical trial of 48 oncolytic virus therapies in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the oncolytic virus therapies. Most of the oncolytic virus therapy in clinical trials are in preclinical phase followed by Phase-I trials.

Download Report Sample Weblink:

https://www.kuickresearch.com/report--global-oncolytic-virus-therapy-market-and-pipeline-outlook-2022.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

Prologue to Oncolytic Virus
1.1 Outline of Oncolytic Virotherapy
1.2 Trail from Genesis to Biogenetics

Primer of Virotherapy in Malignancies
2.1 Oncolytic Viruses towards Cancer
2.2 Approaches for Targeting Tumor Cells
2.2.1 Pro Apoptotic Targeting
2.2.2 Translational Targeting
2.2.3 Transcriptional Targeting
2.2.4 Transductional Targeting

Mechanism Involved in Viral Oncolysis
3.1 Viral Entry into Cancerous Cells
3.2 Efficacy Routes Followed by Oncogenic Viruses
3.3 Mechanism of Tumor Specificity
3.3.1 Defective Anti-Viral Responses
3.3.2 Receptor Targeting for Tumor Selective Intake
3.3.3 Targeting to Tumor Specific Promoters
3.3.4 Viral Gene Deletions
3.3.5 Proteolytic Processing of Virus Particles in Tumor Microenvironment

Cancer Immunotherapy by Oncolytic Viruses
4.1 Stimulation of Antitumor Immune Responses
4.2 Oncolytic Viruses as Cancer Vaccines

Varieties of Viruses Casted as Oncolytic Viruses
5.1 Oncolytic Wild Type Viruses
5.1.1 Reovirus (Respiratory Enteric Orphan Virus)
5.1.2 Vesicular Stomatitis Virus (VSV)
5.1.3 Newcastle Disease Virus (NDV)
5.1.4 Myxoma
5.2 Genetically Engineered Oncolytic Viruses
5.2.1 Adenoviruses
5.2.2 Herpes Simplex Virus
5.2.3 Vaccinia Virus

Approved Oncolytic Virus Therapeutics
6.1 Onxy-15
6.2 RIGVIR
6.3 Talimogene laherparepvec (T-VEC)
6.4 Reolysin

Potential Oncolytic Viruses for Cancers
7.1 Breast Cancer
7.2 Lung Cancer
7.3 Prostate Cancer
7.4 Melanoma
7.5 Brain Tumor
7.6 Blood Cancer

Global Oncolytic Virus Therapy Market Overview
8.1 Preface towards Oncolytic Virus Arcade
8.2 Market Aspects of Approved Oncolytic Viruses
8.3 Oncolytic Virus Clinical Pipeline Overview

Oncolytic Virus Market Dynamics
9.1 Accelerative Parameters
9.2 Major Challenges Faced by Oncolytic Virus

Future Aspects of Oncolytic Viral Therapy

Global Oncolytic Virus Clinical Pipeline by Company, Indication and Phase
11.1 Research
11.2 Preclinical
11.3 Phase-I
11.4 Phase-I/II
11.5 Phase-II
11.6 Phase-II/III
11.7 Phase-III

Marketed Oncolytic Virus Clinical Insight by Company and Indication
12.1 Talimogene Laherparepvec (IMLYGIC)
12.2 H 101 (Oncorine)

No Development Reported Oncolytic Virus Clinical Insight by Company, Indication and Phase
13.1 No Development Reported
13.2 Discontinued

Competitive Landscape
14.1 BioVex
14.2 Cell Genesys
14.3 Crusade Laboratories
14.4 Genelux Corporation
14.5 Jennerex Biotherapeutics
14.6 Lokon Pharma
14.7 Merck
14.8 MultiVir
14.9 Oncolys BioPharma
14.10 Oncolytics Biotech
14.11 Oncos Therapeutics
14.12 PsiOxus Therapeutics
14.13 Shanghai Sunway Bioteh
14.14 Takara Bio
14.15 VCN Biosciences
14.16 ViroTarg
14.17 Vyriad

Figure 1-1: Demonstration of Categorization of Oncolytic Viruses
Figure 1-2: Illustration of Major Events in Clinical Virotherapy
Figure 2-1: Potential Advantages of Oncolytic Viruses over Conventional Therapies
Figure 3-1: The Diagrammatic Representation of Entry of Virions into Cancerous cells
Figure 3-2: Route of Anti-tumoral Efficacy of Oncolytic Viruses
Figure 3-3: Mechanism of Tumor Destruction by Oncolytic Viruses
Figure 3-4: Categorization Followed by Oncolytic Viruses for Tumor Selectivity
Figure 4-1: Demonstration of Phases of Immune Responses Elicited by the Oncolytic Viruses
Figure 5-1: Categorization of Oncolytic Viruses over the Basis of their Behavior
Figure 5-2: Diagrammatic Representation of Oncolysis Shown by Reovirus
Figure 5-3: Mechanism of Oncolytic Behavior of Adenoviruses
Figure 6-1: Mechanism of Action of T-VEC in Treating Melanoma Cancer
Figure 7-1: Selectively Killing of Prostate Cancer Cells by Oncolytic M-Protein Strains of VSV
Figure 7-2: Proposed Treatment of Oncolytic Viruses for Hematological Malignancies
Figure 8-1: Global Oncolytic Virus Pipeline by Phase (%), 2016 till 2022
Figure 8-2: Oncolytic Virus Pipeline by Phase (Numbers), 2016 till 2022
Figure 8-3: Oncolytic Virus Drugs No Development Reported and Discontinued in Clinical Pipeline by Phase (%), 2016 till 2022
Figure 8-4: Oncolytic Virus Drugs No Development Reported and Discontinued in Clinical Pipeline by Phase (Numbers), 2016 till 2022
Figure 9-1: Major Drivers for the Oncolytic Virus Therapies
Figure 9-2: Major Challenges Faced by Oncolytic Viral Therapies
Figure 14-1: Crusade Laboratories - Clinical Pipeline
Figure 14-2: Lokon Pharma - Clinical Pipeline
Figure 14-3: Merck - Clinical Pipeline
Figure 14-4: MultiVir andndash;Clinical Pipeline
Figure 14-5: Oncolys BipoPharma - Clinical Pipeline
Figure 14-6: Oncos Therapeutics - Clinical stage
Figure 14-7: Vyriad - Clinical Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.